T hrombolytic therapy in patients with acute myocardial infarction has been shown to recanalize occluded coronary arteries, preserve left ventricular function, and reduce mortality. At present, coronary thrombolysis is primarily performed with streptokinase or with alteplase, a preparation of recombinant tissue-type plasminogen activator (rt-PA).l The main advantages of streptokinase are its low cost and relative safety, whereas the main shortcomings are its limited efficacy for coronary recanalization and its immunogenicity, which predisposes to allergic reactions and to resistance to repeated administration. The main advantages of alteplase are its higher efficacy for coronary recanalization and its lack of immunogenicity, whereas its main disadvantage is its high cost. Thus, thrombolytic agents with higher thrombolytic potency, reduced side effects, and/or lower cost would be desirable.
Staphylokinase (STA), a protein of 136 amino acids that does not contain disulfide bridges, is produced by transduced Staphylococcus aureus strains and has been known for more than 40 years to have profibrinolytic properties. Its mechanism of action, its in vitro fibrinolytic properties, and its in vivo thrombolytic properties in experimental animal models have been evaluated to some extent. 2 Like streptokinase, staphylokinase is not an enzyme, but it forms a 1:1 stoichiometric complex with plasminogen that then activates other plasminogen molecules.3'4 However, whereas the streptokinase-plasminogen complex undergoes an intramolecular transition without peptide bond cleavage, which results in exposure of a titrable active site in the plasminogen molecule,5 activation of the staphylokinase-plasminogen complex requires its conversion to plasmin.6 Furthermore, the staphylokinase-plasmin complex is very rapidly inhibited by a2-antiplasmin, whereas the streptokinase-plasmin complex is not. 7, 8 The 18 ,000, and it had NH2-terminal sequence Ser-Ser-Ser-PheAsp-.17 After filtration on 0.22-,um millipore filters, the materials were sterile and virus free by routine screening for human pathogenic viruses; they were obtained at a concentration of %1 mg/mL, with a specific activity of 185,000 arbitrary units per milligram2 and an endotoxin content of 10+7 units/mg. Bolus injection at a dose of 3 mg/kg in mice did not produce weight loss or reduced weight gain within 8 days.17
Patients
Patients were studied after giving informed consent, and the protocol was approved by the Human Studies Committee of the University of Leuven. The following criteria were applied for inclusion: a history of chest pain typical of myocardial ischemia persisting for at least 30 minutes, a >2-mm ST-segment elevation in at least two frontal planes or two precordial ECG leads, and feasibility of initiating thrombolytic therapy within 6 hours of the onset of symptoms. Criteria for exclusion included major illness other than coronary artery disease, contraindications to thrombolytic agents, and concomitant anticoagulation.
After entry into the study in the emergency ward, the patient was immediately transferred to the cardiac catheterization laboratory, where selective coronary arteriography was immediately performed from the documented, an intravenous bolus injection of 1 mg of STAR was given over 2 minutes followed by an infusion of the remaining 9 mg over 30 minutes. Arteriography of the occluded coronary artery was repeated at 10-minute intervals during the infusion, and the angiographic evaluation was terminated after the 40-minute angiogram. When coronary reperfusion was not obtained within 40 minutes, the patients were immediately treated with 100 mg rt-PA (Actilyse, Boehringer Ingelheim) given over 90 minutes. At 30 minutes, all patients were also given 320 mg aspirin, and a continuous intravenous infusion of heparin (1,000 units/hr) was started.
Blood Samples
Blood samples were collected on citrate (final concentration, 0.01 M) before and 0, 10, 20, 30, 35, 40, 45, 60, 75, and 90 minutes after the start of the infusion of STAR. The fibrinogen and a2-antiplasmin were assayed as described elsewhere.14 Fibrin fragment D-dimer and STAR-related antigen levels in plasma were assayed with enzyme-linked immunosorbent assays using two murine monoclonal antibodies raised with the purified antigens. Additional blood samples were obtained at 4, 7, and 14-35 days for the determination of STARneutralizing antibodies using the staphylokinase reactivity assay with 350 ,uL citrated plasma, as described elsewhere. 13 The pharmacokinetic parameters of the disposition of STAR from blood were derived from serial measurements of plasma antigen levels after the end of the infusion. The data describing the postinfusion disappearance of STAR-related antigen from plasma were plotted on semilogarithmic paper and fitted with a sum of two exponential terms, C(t)=Re`+Se-by graphical curve peeling. 18 The variables A and B were first calculated (assuming steady state at the end of the infusion) using the formulas A=RXoa/k. and B=SX43/ k., where X. is the total administered dose and k, is the rate of infusion. Pharmacokinetic parameters were calculated from the coefficients A and B and exponents a and ,B using standard formulas derived by Gibaldi The concentration of STAR-related antigen in blood toward the end of the infusion of 10 mg STAR over 30 minutes increased to between 0.9 and 1.7 ,ug/mL (Table  3) . After the end of the infusion, STAR-related antigen disappeared from plasma in a biphasic mode with an initial half-life of 6.3+±0.6 minutes and a terminal halflife of 37+15 minutes, corresponding to a plasma clearance of 270±100 mL/min. STAR-neutralizing activity in plasma was not consistently detectable at baseline and at 4-7 days after the STAR infusion (Table 2) . However, at 14-35 days, neutralizing titers of 12-42 ,ug/mL plasma were found. The STAR-neutralizing activity consisted most likely of antibodies, because it could be quantitatively removed by adsorption on protein A-Sepharose. The antibodies induced after STAR administration did not cross-react with streptokinase.
Discussion
This study evaluates the feasibility of intravenous infusion of 10 mg STAR for coronary thrombolysis in patients with acute myocardial infarction. The administration scheme used was based on our previous experience in baboons, which suggested that STAR had a similar potency as streptokinase for venous clot lysis but a higher potency for arterial clot lysis.14 Intravenous infusion of STAR at this dose indeed induced coronary artery recanalization within 40 minutes in four of five patients. Recanalization was not associated with systemic fibrinolytic activation and fibrinogen breakdown.
Neutralizing antibodies could not be detected at baseline and within 1 week after administration of STAR but were consistently observed after 14-35 days. These induced antibodies did not, however, cross-react with streptokinase. Thus, with respect to immunogenicity, our initial observations in humans are not as encouraging as our experience in baboons, where three The plasma concentration vs. time data were fitted with the equation C(t)=Re-al+Se-0, and pharmacokinetic parameters were derived as described in "Methods."
Results of one patient who received alteplase during the observation period relevant for pharmacokinetic analysis were not included in this study.
of four animals did not even produce neutralizing antibodies after a five-times repeated administration of STAR at weekly intervals. However, we have recently obtained evidence (Declerck et al, unpublished) that the prevalence of anti-STAR antibodies in the general population is lower than that of antistreptokinase antibodies. Thus, the initial anticipation that STAR might produce fewer allergic reactions than streptokinase is not definitively invalidated by the present demonstration of its immunogenicity. Although the restriction to single use as a result of immunogenicity would probably apply to both streptokinase and STAR, the absence of cross-reactivity of induced antibodies suggests that the use of both substances would not be mutually exclusive.
Although the small number of patients studied precludes valid estimation of the frequency of coronary recanalization with STAR and of the adequacy of the dose used, this feasibility study suggests that intravenous infusion of 10 mg STAR may produce fibrinspecific coronary thrombolysis. Definition of the relative therapeutic benefit or lack thereof will require more detailed initial dose-finding studies followed by randomized clinical trials against other thrombolytic agents.
The STAR material used in the present study was obtained by expression of the staphylokinase gene cloned from the genomic DNA of a transduced S. aureus strain in E. coli using standard recombinant DNA techniques developed in the 1970s.2 The small size of the protein and its lack of disulfide bridges make it ideally suited for large-scale production in E. coli.
Conclusion
The results of the present initial pilot study in humans confirm those of our previous studies in animals with venous or coronary artery thrombosis13'14 that showed that STAR is an effective thrombolytic agent and extend these observations to patients with evolving myocardial infarction. The present preliminary experience may provide a basis for the design of future dose-finding studies and controlled clinical trials with this agent.
